Omega-3 acid ethyl esters 90
Omacor contains highly purified omega-3 polyunsaturated fatty acids.
Omacor belongs to a group of medicines that lower cholesterol and triglyceride levels.
Omacor is used:
If any of the above statements apply to you, do not take the medicine and consult your doctor.
Before taking Omacor, consult your doctor or pharmacist:
If you are taking medicines that prevent blood clots in arteries, such as warfarin, you may need to have additional blood tests and adjust the dose of blood-thinning medicines.
Tell your doctor or pharmacist about all the medicines you are taking, or have recently taken, and about any medicines you plan to take.
Capsules should be taken with meals. This will help avoid stomach and gastrointestinal problems.
Caution should be exercised when using Omacor in patients over 70 years of age.
Omacor should not be used in children.
Omacor should not be used during pregnancy and breastfeeding, unless your doctor decides it is absolutely necessary.
Before taking any medicine, consult your doctor or pharmacist.
It is unlikely that Omacor will affect your ability to drive or use machines.
Omacor contains soybean oil. If you are allergic to peanuts or soy, do not take Omacor.
Always take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The usual dose is two capsules per day, as recommended by your doctor.
If the effect of the medicine is not sufficient, your doctor may increase the dose to four capsules per day.
Accidental overdose is unlikely to cause concern, as it usually does not require special treatment. However, consult your doctor or pharmacist.
If you miss a dose, take it as soon as you remember, unless it is almost time for your next dose. In this case, take the next dose at the scheduled time. Do not take a double dose (twice the dose recommended by your doctor) to make up for the missed dose.
If you have any doubts about taking the medicine, consult your doctor or pharmacist.
Like all medicines, Omacor can cause side effects, although not everybody gets them.
The following side effects may occur during treatment with Omacor:
Other side effects that have occurred in a small number of people, but the exact frequency is unknown
If any of the side effects get worse, or if you notice any side effects not listed in this leaflet, please inform your doctor or pharmacist.
If you experience any side effects, including those not listed in this leaflet, please inform your doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep the medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Store in a temperature below 25°C, in the original packaging. Do not freeze.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The active substance of Omacor is omega-3 ethyl esters.
1000 mg of omega-3 ethyl esters 90 contains 460 mg of ethyl ester of eicosapentaenoic acid (EPA) and 380 mg of ethyl ester of docosahexaenoic acid (DHA) (these substances are called omega-3 polyunsaturated fatty acids), and as an antioxidant 4 mg of D-α-tocopherol (mixed with vegetable oil, e.g., soybean oil).
Capsule shell: gelatin, glycerol, purified water, lecithin (soy), fractionated coconut oil, isopropyl alcohol, anhydrous ethanol.
Omacor is available in the form of transparent, soft capsules containing a light yellow oil.
The pack contains 28 capsules.
For more detailed information, please contact the marketing authorization holder or the parallel importer.
BASF AS
Lilleakerveien 2B
0283 Oslo
Norway
BASF AS
Framnesveien 41
3222 Sandefjord
Norway
PIERRE FABRE MÉDICAMENT PRODUCTION
Le Payrat
46000 Cahors
France
TDF SA
ul. Zbąszyńska 3
91-342 Łódź
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Marketing authorization number in Romania, the country of export: 9639/2017/01
Parallel import authorization number: 301/24
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.